Möchten Sie immer auf dem neuesten Stand bleiben?

- Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 --- Dopavision, a clinical-stage company pioneering the...

- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of tailored cell therapy shipment solutions ...

Expanded partnership of two leading innovatorsResomer® used in commercial 3D-printed implants for both soft and hard tissue applicationsBellaSeno receives market authorization for fully resorbable...

- Leading European T cell therapy researcher adds further scientific expertise ROTTERDAM, February 23, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery...

- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...

- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...

- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...

- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...

- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...

- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...